Business Context and Reporting Period
This Form 8-K is a current report filed by Histogenics Corporation (HSGX) on June 21, 2019, regarding events occurring on June 19, 2019. The company is an emerging growth company listed on The Nasdaq Capital Market. The filing primarily addresses ongoing delisting proceedings due to non-compliance with Nasdaq listing standards and the status of a proposed merger with Ocugen, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on regulatory compliance and corporate governance events rather than financial performance data.
Material Changes and Corporate Events
- Nasdaq Delisting Notices: Histogenics received a "June Letter" from Nasdaq on June 19, 2019, notifying the company that it failed to regain compliance with the Market Value Rule (requiring a market value of listed securities of at least $35 million). This failure serves as an additional basis for delisting.
- Merger Extension: A Nasdaq Hearings Panel previously granted Histogenics an extension until September 30, 2019, to complete a merger with Ocugen, Inc. The Panel will consider the new Market Value Rule failure in its decision regarding continued listing.
- Board Resignations: Directors Kevin Rakin and Michael Lewis resigned effective June 20, 2019, to devote time to other commitments. The Board reduced its size from six to four members.
- Board Appointment: Joshua Baltzell was appointed to the Audit Committee effective June 20, 2019, to maintain compliance with Nasdaq board composition requirements.
Guidance, Outlook, and Risks
Outlook and Merger Status: The company intends to present its views regarding the Market Value Rule deficiency to the Nasdaq Panel by June 26, 2019. The proposed merger with Ocugen remains subject to stockholder approval and customary closing conditions. Upon closing, the combined entity is expected to trade under the symbol "OCGN," though there is no assurance the combined company will meet initial listing requirements.
Risks and Contingencies: The filing highlights significant risks, including the potential failure to satisfy merger conditions, uncertainties regarding the timing of the merger, and the risk of delisting if compliance is not maintained. Additional risks involve the clinical development of Ocugen's product candidates, potential dilution from financing, and the ability to secure sufficient capital for operations.
Investor Verification Checklist
- Verify the outcome of the Nasdaq Hearings Panel decision regarding the June 19, 2019, Market Value Rule deficiency.
- Confirm the status of the definitive proxy statement/prospectus for the Histogenics-Ocugen merger.
- Monitor the combined entity's ability to meet Nasdaq initial listing requirements post-merger.
- Review the final composition of the Histogenics Board of Directors following the June 20, 2019, changes.
- Assess the timeline for the merger closing relative to the September 30, 2019, deadline.